Study conducted between Sept. 2011 and Jun. 2012 by Laurent MEESCHAERT

Compliance with a certain number of ethical criteria (environmental friendliness, corporate governance, social policy) is still some of investors’ core concerns.

However, asset management usually neglects the “bioethics” criteria.

With this in mind, I conducted a survey of 44 pharmaceutical and cosmetics laboratories listed on the stock exchange in order to find out about their practices in the area of research on stem cells.

The purpose is to encourage medical research that is both of a high-performance nature and that fully respects human dignity.

Survey's author